Elnegris, H., Khalil, S., Badran, D., Galhom, R. (2021). Therapeutic Efficacy of Melatonin Pretreated Bone Marrow Mesenchymal Stem Cells Versus Mesenchymal Stem Cells in Experimental Diabetic Cardiomyopathy in Rat. Journal of Medical Histology, 5(2), 134-153. doi: 10.21608/jmh.2022.165071.1104
Heba Elnegris; Sahar Khalil; Dahlia Badran; Rania Galhom. "Therapeutic Efficacy of Melatonin Pretreated Bone Marrow Mesenchymal Stem Cells Versus Mesenchymal Stem Cells in Experimental Diabetic Cardiomyopathy in Rat". Journal of Medical Histology, 5, 2, 2021, 134-153. doi: 10.21608/jmh.2022.165071.1104
Elnegris, H., Khalil, S., Badran, D., Galhom, R. (2021). 'Therapeutic Efficacy of Melatonin Pretreated Bone Marrow Mesenchymal Stem Cells Versus Mesenchymal Stem Cells in Experimental Diabetic Cardiomyopathy in Rat', Journal of Medical Histology, 5(2), pp. 134-153. doi: 10.21608/jmh.2022.165071.1104
Elnegris, H., Khalil, S., Badran, D., Galhom, R. Therapeutic Efficacy of Melatonin Pretreated Bone Marrow Mesenchymal Stem Cells Versus Mesenchymal Stem Cells in Experimental Diabetic Cardiomyopathy in Rat. Journal of Medical Histology, 2021; 5(2): 134-153. doi: 10.21608/jmh.2022.165071.1104
Therapeutic Efficacy of Melatonin Pretreated Bone Marrow Mesenchymal Stem Cells Versus Mesenchymal Stem Cells in Experimental Diabetic Cardiomyopathy in Rat
1Department of Histology and Cell Biology, Faculty of Medicine, Zagazig University, Zagazig, Badr University in Cairo, Cairo,
2Suez Canal University, Ismailia, Department of Biochemistry Molecular Biology, Faculty of Medicine,
3Suez Canal University, Ismailia, & Badr University in Cairo, Cairo, Department of Human Anatomy and Embryology,
4Suez Canal University, Ismailia, Badr University in Cairo, Cairo, &Tissue Culture Unit, Center of Excellence in Molecular and Cellular Medicine (CEMCM), Suez Canal University. Ismailia, Egypt
Abstract
Background: Diabetic cardiomyopathy (DCM) is a common condition that is associated with morbidity and mortality. With the medical advancement in cell treatment, stem cell therapy has a potential therapeutic strategy for DCM. Objectives: We aim to evaluate the possible therapeutic effects of Mesenchymal stem cells (MSCs) versus melatonin (MLT) preconditioned-MSCs in induced diabetic cardiomyopathy in rats. Materials and Methods: Forty-five male adult albino rats were divided into four groups. Group I: Control group. Group < br />II: Diabetic group: Rats received single intraperitoneal injection of streptozotocin STZ (50 mg/kg body weight). Group < br />III: DC treated with MSCs. Group IV: DC treated with MLT preconditioned-MSCs. Histological, ultrastructural and immunohistochemical studies were performed on left ventricle myocardium. We also estimated the survival of MLTpreconditioned MSCs in vitro. Bcl-2, Casp-3, interleukin 1 (IL-1), and interleukin 10 (IL-10) expression were measured using real-time PCR in tissue homogenates. Results: Our findings revealed a significant increase in immunohistochemical expression of apoptotic markers in the diabetic group, as well as a disruption of the normal cardiac histological ultrastructure. Melatonin improved MSCs survival in vitro and altered apoptotic markers. In addition, the melatonin-preconditioned MSC group showed a significant increase in B-cell lymphoma 2 (Bcl-2) mRNA expression and a significant decrease in Casp-3. Enhanced immunomodulatory behavior was obvious by a significant attrition of the mRNA expression of IL-1β (inflammatory-agonist) and a significant altitude of IL-10 (inflammatory-antagonist). Conclusion: The melatonin-preconditioning of MSCs enhance their survival and immunomodulatory activities and precisely restored cardiac histology. Thus, it unveils an encouraging interference of DC.
View on SCiNiTO
Top